Maximus (NYSE:MMS) Director Sells $53,609.50 in Stock

Maximus, Inc. (NYSE:MMS) Director Jan Madsen sold 742 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $72.25, for a total value of $53,609.50. Following the completion of the sale, the director directly owned 20,795 shares of the company’s stock, valued at $1,502,438.75. The trade was a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Maximus Stock Performance

NYSE MMS traded up $0.55 during trading on Tuesday, reaching $72.11. The company’s stock had a trading volume of 376,574 shares, compared to its average volume of 695,145. Maximus, Inc. has a twelve month low of $64.68 and a twelve month high of $100.00. The firm has a market cap of $3.93 billion, a price-to-earnings ratio of 10.98 and a beta of 0.59. The business’s fifty day moving average price is $84.14 and its 200-day moving average price is $85.56. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.34 and a current ratio of 2.34.

Maximus (NYSE:MMS) last announced its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share for the quarter, beating the consensus estimate of $1.84 by $0.01. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.37 billion. Maximus had a return on equity of 25.30% and a net margin of 6.92%.The company’s revenue was down 4.1% on a year-over-year basis. During the same period last year, the business posted $1.61 EPS. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. As a group, analysts anticipate that Maximus, Inc. will post 6.15 EPS for the current fiscal year.

Maximus Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a dividend of $0.33 per share. This is a positive change from Maximus’s previous quarterly dividend of $0.30. The ex-dividend date of this dividend was Friday, February 13th. This represents a $1.32 annualized dividend and a dividend yield of 1.8%. Maximus’s dividend payout ratio is presently 20.09%.

Hedge Funds Weigh In On Maximus

Several hedge funds and other institutional investors have recently modified their holdings of MMS. Dimensional Fund Advisors LP increased its holdings in Maximus by 5.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,965,916 shares of the health services provider’s stock valued at $169,700,000 after purchasing an additional 96,343 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Maximus by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 1,482,079 shares of the health services provider’s stock valued at $127,952,000 after buying an additional 5,130 shares in the last quarter. Boston Partners raised its holdings in shares of Maximus by 47.0% during the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after buying an additional 308,892 shares during the period. Reinhart Partners LLC. lifted its position in Maximus by 0.8% during the 3rd quarter. Reinhart Partners LLC. now owns 921,578 shares of the health services provider’s stock worth $84,206,000 after acquiring an additional 7,722 shares in the last quarter. Finally, River Road Asset Management LLC boosted its holdings in Maximus by 236.1% in the 4th quarter. River Road Asset Management LLC now owns 823,262 shares of the health services provider’s stock worth $71,064,000 after acquiring an additional 578,326 shares during the period. 97.21% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Maximus from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Weiss Ratings cut Maximus from a “buy (b)” rating to a “hold (c+)” rating in a research report on Tuesday, February 24th. Finally, Zacks Research upgraded shares of Maximus from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Maximus currently has an average rating of “Buy”.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.